Skip to main content
Clinical Trials/NCT02863315
NCT02863315
Unknown
Not Applicable

The Effects of Anodal Transcutaneous Spinal Direct Current Stimulation on Chronic Neuropathic Pain After Spinal Cord Injury: Pilot Study

Seoul National University Hospital1 site in 1 country10 target enrollmentAugust 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Neuropathic Pain
Sponsor
Seoul National University Hospital
Enrollment
10
Locations
1
Primary Endpoint
Numeric rating scale (NRS) for neuropathic pain
Last Updated
9 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the analgesic effect of transcutaneous spinal direct current stimulation (tsDCS) applied on spinal cord in patients with spinal cord injury who have chronic neuropathic pain.

Detailed Description

Twenty patients with spinal cord injury and bilateral neuropathic pain received single sessions of both sham and anodal tsDCS (2 mA) over tenth thoracic vertebra for 20 min (reference electrodes on the head vertex). Treatment order was randomly assigned. A evaluator rated the pain using the visual analogue scale for pain, Patient Global Assessment and Present Pain Intensity.

Registry
clinicaltrials.gov
Start Date
August 2016
End Date
October 2017
Last Updated
9 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Hyung-ik Shin

Professor

Seoul National University Hospital

Eligibility Criteria

Inclusion Criteria

  • cervical or upper thoracic complete motor spinal cord injury, at least 6 months after SCI, 20\<=age\<90
  • neuropathic pain (LANSS score \>= 12), stable chronic pain for at least the three preceding months but not over 5 years
  • score higher than or equal to 4 cm (0 cm = 'no pain' and 10 cm = 'worst possible pain') on the visual ana- logue scale (VAS) for pain perception at the baseline/start of the treatment
  • refractoriness to drugs for pain relief - such as tricyclic antidepressants, antiepileptic drugs, and/or narcot- ics (pain resistant to at least two of these drugs supplied in ade- quate dosages for 6 months)
  • informed consent

Exclusion Criteria

  • patients with any clinically significant or unstable medical or progressive neurologic disorder
  • contraindication for electrial stimulation such as pacemaker implant
  • Women of childbearing age or pregnancy
  • significant cognitive deficit
  • Syringomyelia
  • neuropsychiatric comorbidity
  • depressive disorder (as indicated by a score of 10 greater on the Beck Depression Inventory)
  • history of substance abuse
  • skin defect under the electrodes
  • progressive neurological disease or other secondary conditions that could impact neuropathic pain

Outcomes

Primary Outcomes

Numeric rating scale (NRS) for neuropathic pain

Time Frame: Baseline NRS (average NRS over the preceding 24h), Change from Baseline NRS at 0, 60 and 120 minutes after the start of the stimulation

On a scale of 0 to 10, with 0 being no pain at all and 10 being the worst pain imaginable

Secondary Outcomes

  • Patient Global Assessment (PGA)(Baseline PGA (average PGA over the preceding 24h), Change from Baseline PGA at 0, 60 and 120 minutes after the start of the stimulation)
  • Present Pain Intensity (PPI)(Baseline PPI (average PPI over the preceding 24h), Change from Baseline PPI at 0, 60 and 120 minutes after the start of the stimulation)

Study Sites (1)

Loading locations...

Similar Trials